Tags

Type your tag names separated by a space and hit enter

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Clin Infect Dis. 2004 Nov 15; 39(10):1520-3.CI

Abstract

Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Sindermann H
Medical Research and Development, Zentaris GmbH, Frankfurt am Main, Germany. herbert.sindermann@zentaris.com
Engel KR
No affiliation info available
Fischer C
No affiliation info available
Bommer W
No affiliation info available
Miltefosine Compassionate Use Program
No affiliation info available

MeSH

Administration, OralAdultAntiprotozoal AgentsFemaleHIV InfectionsHumansImmunocompromised HostLeishmaniasisMaleMiddle AgedPhosphorylcholine

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15546090

Citation

Sindermann, Herbert, et al. "Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients With HIV Infection." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 39, no. 10, 2004, pp. 1520-3.
Sindermann H, Engel KR, Fischer C, et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis. 2004;39(10):1520-3.
Sindermann, H., Engel, K. R., Fischer, C., & Bommer, W. (2004). Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 39(10), 1520-3.
Sindermann H, et al. Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients With HIV Infection. Clin Infect Dis. 2004 Nov 15;39(10):1520-3. PubMed PMID: 15546090.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. AU - Sindermann,Herbert, AU - Engel,Kirsten R, AU - Fischer,Christina, AU - Bommer,Wolfgang, AU - ,, Y1 - 2004/10/18/ PY - 2004/03/31/received PY - 2004/07/07/accepted PY - 2004/11/17/pubmed PY - 2005/11/9/medline PY - 2004/11/17/entrez SP - 1520 EP - 3 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 39 IS - 10 N2 - Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/15546090/Oral_miltefosine_for_leishmaniasis_in_immunocompromised_patients:_compassionate_use_in_39_patients_with_HIV_infection_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/425359 DB - PRIME DP - Unbound Medicine ER -